Oruka Therapeutics ($ORKA) Insider Trading & Smart Money Activity
Oruka Therapeutics, Inc. ($ORKA) has 16 insider trades, 1 13F position change and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 9 insiders sold ($7.09M), net -$7.09M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 9
- Net insider $ (12 mo)
- -$7.09M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 1
- Analyst ratings on file
- 1
ORKA insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 8 · $2.68M | 0 / 0 | 0 / 1 |
| Q3 2026 | 0 | 2 · $987.45K | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 3 · $3.42M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ORKA insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Goncalves JoanaChief Medical Officer | Sell (Open-market sale) 10b5-1 | 7K sh | $523.65K | Read | ||||||
| Insider | Agarwal ArjunSenior Vice President, Finance | Sell (Open-market sale) 10b5-1 | 10K sh | $805.89K | Read | ||||||
| Insider | Klein Lawrence OttoChief Executive Officer | Sell (Open-market sale) 10b5-1 | 25K sh | $2.09M | -7.4% | — | |||||
| Insider | Quinlan Paul TGeneral Counsel | Sell (Open-market sale) 10b5-1 | 10K sh | $936.42K | -9.8% | Read | |||||
| Insider | Agarwal ArjunSenior Vice President, Finance | Sell (Open-market sale) 10b5-1 | 533 sh | $51.03K | -9.8% | — | |||||
| Analyst | UBS | Reiterates to buy | PT $130 | -9.5% | +3.5% | Read | |||||
| Insider | Arjun AgarwalSenior Vice President, Finance | Sell (Open-market sale) 10b5-1 | 1.59K sh | $128.47K | +8.3% | +8.4% | — | ||||
| Insider | Sandler Laura LeeChief Operating Officer | Sell (Open-market sale) | 600 sh | $41.81K | +24.0% | +25.8% | Read | ||||
| Insider | Paul QuinlanGeneral Counsel | Sell (Open-market sale) | 733 sh | $51.08K | +24.0% | +25.8% | Read | ||||
| Insider | Klein Lawrence OttoChief Executive Officer | Sell (Open-market sale) | 1.73K sh | $120.49K | +24.0% | +25.8% | Read | ||||
| Insider | Joana GoncalvesChief Medical Officer | Sell (Open-market sale) 10b5-1 | 7.95K sh | $550.60K | +24.0% | +25.8% | Read | ||||
| Insider | Joana GoncalvesChief Medical Officer | Buy (Option exercise) | 7K sh | $51.24K | +24.0% | +25.8% | Read | ||||
| Insider | Arjun AgarwalSenior Vice President, Finance | Sell (Open-market sale) 10b5-1 | 395 sh | $27.53K | +24.0% | +25.8% | Read | ||||
| Insider | Carl Dambkowski | Sell (Open-market sale) 10b5-1 | 12.58K sh | $882.19K | +22.2% | +21.0% | — | ||||
| Insider | Carl Dambkowski | Sell (Open-market sale) 10b5-1 | 12.58K sh | $882.19K | +22.2% | +21.0% | — | ||||
| Insider | Arjun AgarwalSenior Vice President, Finance | Sell (Option exercise) | 9.46K sh | +22.2% | +21.0% | Read | |||||
| Insider | Arjun AgarwalSenior Vice President, Finance | Buy (Option exercise) | 9.46K sh | $150.17K | +22.2% | +21.0% | Read | ||||
| 13F | Avoro Capital Advisors | Sold out | -1.33M sh | -2.1% | +11.2% | Read |
1W / 1M / 6M = how ORKA moved from the trade or filing date.
Insider trading in ORKA: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Goncalves Joana | Chief Medical Officer | 1 | -$523.65K | Oct 15, 2026 | |
| Agarwal Arjun | Senior Vice President, Finance | 2 | -$856.92K | Oct 12, 2026 | |
| Klein Lawrence Otto | Chief Executive Officer | 2 | -$2.21M | Oct 1, 2026 | |
| Quinlan Paul T | General Counsel | 1 | -$936.42K | Sep 21, 2026 | |
| Arjun Agarwal | Senior Vice President, Finance | 4 | -$156K | Jun 22, 2026 | |
| Joana Goncalves | Chief Medical Officer | 2 | -$550.60K | Jun 15, 2026 | |
| Sandler Laura Lee | Chief Operating Officer | 1 | -$41.81K | Jun 15, 2026 | |
| Paul Quinlan | General Counsel | 1 | -$51.08K | Jun 15, 2026 | |
| Carl Dambkowski | 2 | -$1.76M | Jun 12, 2026 |
Institutions moving ORKA (13F)
Analyst ratings on ORKA
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| UBS | Reiterates | buy | $130 | -9.5% | +3.5% | Read |
Frequently asked questions
Are ORKA insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 9 insiders made 13 open-market sales worth $7.09M, a net -$7.09M.
What is the latest insider trade in ORKA?
Goncalves Joana, Chief Medical Officer filed a sell (open-market sale) of 7K sh worth $523.65K on Oct 15, 2026.
Which institutions changed their ORKA positions?
Recent 13F filers moving the stock include Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.